PT - JOURNAL ARTICLE AU - McCullum, Lucas AU - Mulder, Samuel AU - West, Natalie AU - Aghoghovbia, Robert AU - Ali, Alaa Mohamed Shawky AU - Scott, Hayden AU - Salzillo, Travis C. AU - Ding, Yao AU - Dresner, Alex AU - Subashi, Ergys AU - Ma, Dan AU - Stafford, R. Jason AU - Hwang, Ken-Pin AU - Fuller, Clifton D. TI - Technical Development and In Silico Implementation of SyntheticMR in Head and Neck Adaptive Radiation Therapy: A Prospective R-IDEAL Stage 0/1 Technology Development Report AID - 10.1101/2024.08.29.24312591 DP - 2024 Jan 01 TA - medRxiv PG - 2024.08.29.24312591 4099 - http://medrxiv.org/content/early/2024/09/30/2024.08.29.24312591.short 4100 - http://medrxiv.org/content/early/2024/09/30/2024.08.29.24312591.full AB - Objective The purpose of this study was to investigate the technical feasibility of integrating the quantitative maps available from SyntheticMR into the head and neck adaptive radiation oncology workflow. While SyntheticMR has been investigated for diagnostic applications, no studies have investigated its feasibility and potential for MR-Simulation or MR-Linac workflow. Demonstrating the feasibility of using this technique will facilitate rapid quantitative biomarker extraction which can be leveraged to guide adaptive radiation therapy decision making.Approach Two phantoms, two healthy volunteers, and one patient were scanned using SyntheticMR on the MR-Simulation and MR-Linac devices with scan times between four to six minutes. Images in phantoms and volunteers were conducted in a test/retest protocol. The correlation between measured and reference quantitative T1, T2, and PD values were determined across clinical ranges in the phantom. Distortion was also studied. Contours of head and neck organs-at-risk (OAR) were drawn and applied to extract T1, T2, and PD. These values were plotted against each other, clusters were computed, and their separability significance was determined to evaluate SyntheticMR for differentiating tumor and normal tissue.Main Results The Lin’s Concordance Correlation Coefficient between the measured and phantom reference values was above 0.98 for both the MR-Sim and MR-Linac. No significant levels of distortion were measured. The mean bias between the measured and phantom reference values across repeated scans was below 4% for T1, 7% for T2, and 4% for PD for both the MR-Sim and MR-Linac. For T1 vs. T2 and T1 vs. PD, the GTV contour exhibited perfect purity against neighboring OARs while being 0.7 for T2 vs. PD. All cluster significance levels between the GTV and the nearest OAR, the tongue, using the SigClust method was p < 0.001.Significance The technical feasibility of SyntheticMR was confirmed. Application of this technique to the head and neck adaptive radiation therapy workflow can enrich the current quantitative biomarker landscape.Competing Interest StatementAD has received related research support from Elekta AB and unrelated royalties / licenses from Resoundant LLC. KH has received related investigational software / research support from SyntheticMR AB and unrelated research support from GE Healthcare. CDF has received related travel, speaker honoraria and/or registration fee waiver from: Elekta AB and unrelated travel, speaker honoraria and/or registration fee waiver from: The American Association for Physicists in Medicine; the University of Alabama-Birmingham; The American Society for Clinical Oncology; The Royal Australian and New Zealand College of Radiologists; The American Society for Radiation Oncology; The Radiological Society of North America; and The European Society for Radiation Oncology.Funding StatementLM is supported by a National Institutes of Health (NIH) Diversity Supplement (R01CA257814-02S2). SM and CDF are supported by the NIH National Institute of Dental and Craniofacial Research (NIDCR) Academic Industrial Partnership (R01DE028290). NW is supported by a NIH National Institute of Dental and Craniofacial Research (NIDCR) Academic Industrial Partnership Grant (R01DE028290). RA is supported through the University of Texas MD Anderson Cancer Center Division of Radiation Oncology and The Sterling Foundation. TCS is supported by The University of Texas Health Science Center at Houston, the Center for Clinical and Translational Sciences TL1 Program (TL1TR003169). DM is supported by the National Cancer Institute (NCI) (R01CA269604, R01CA282516, and R01CA292091). CDF has received unrelated funding and salary support from: the Administrative Supplement to Support Collaborations to Improve AIML-Readiness of NIH-Supported Data (R01DE028290-04S2); NIDCR Establishing Outcome Measures for Clinical Studies of Oral and Craniofacial Diseases and Conditions award (R01DE025248); NSF/NIH Interagency Smart and Connected Health (SCH) Program (R01CA257814); NIH National Institute of Biomedical Imaging and Bioengineering (NIBIB) Research Education Programs for Residents and Clinical Fellows Grant (R25EB025787); NIH NIDCR Exploratory/Developmental Research Grant Program (R21DE031082); NIH/NCI Cancer Center Support Grant (CCSG) Pilot Research Program Award from the UT MD Anderson CCSG Radiation Oncology and Cancer Imaging Program (P30CA016672); Patient-Centered Outcomes Research Institute (PCS-1609-36195) sub-award from Princess Margaret Hospital; National Science Foundation (NSF) Division of Civil, Mechanical, and Manufacturing Innovation (CMMI) grant (NSF 1933369). CDF receives grant and infrastructure support from MD Anderson Cancer Center via: the Charles and Daneen Stiefel Center for Head and Neck Cancer Oropharyngeal Cancer Research Program; the Program in Image-guided Cancer Therapy; and the NIH/NCI Cancer Center Support Grant (CCSG) Radiation Oncology and Cancer Imaging Program (P30CA016672).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participants provided written informed consent. Volunteers were consented to an internal volunteer imaging protocol (PA15-0418), both approved by the institutional review board at The University of Texas MD Anderson Cancer Center.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll relevant anonymized SyntheticMR unprocessed (pre-SyMRI) DICOM files are to be made publicly available after manuscript acceptance at the following DOI: 10.6084/m9.figshare.26835715 The accompanying code for image visualization and statistical analysis will be made publicly available at the following URL: https://github.com/Lucas-Mc/SyntheticMR_R-IDEAL_0-1 https://doi.org/10.6084/m9.figshare.26835715 https://github.com/Lucas-Mc/SyntheticMR_R-IDEAL_0-1.git